U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H29N5O8S2.ClH
Molecular Weight 604.096
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFCAPENE PIVOXIL HYDROCHLORIDE

SMILES

Cl.[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=C/CC)\C3=CSC(N)=N3)C(=O)OCOC(=O)C(C)(C)C

InChI

InChIKey=ALPFRUJYOAKQQR-CQZSJNSUSA-N
InChI=1S/C23H29N5O8S2.ClH/c1-5-6-12(13-9-38-21(24)26-13)16(29)27-14-17(30)28-15(11(7-34-22(25)33)8-37-18(14)28)19(31)35-10-36-20(32)23(2,3)4;/h6,9,14,18H,5,7-8,10H2,1-4H3,(H2,24,26)(H2,25,33)(H,27,29);1H/b12-6-;/t14-,18-;/m1./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18347113 | https://www.ncbi.nlm.nih.gov/pubmed/26440444

Cefcapene is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcapene binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Giasion

Approved Use

GIASION is indicated for treatment of the following infections caused by susceptible microorganisms: (see section 5.1 pharmacodynamic properties): Pharyngo-acute tonsillitis Acute maxillary sinusitis Acute exacerbation of chronic bronchitis Community acquired pneumonia, mild or moderate Infections uncomplicated skin and skin structures, such as cellulitis, wound infections, abscesses, folliculitis, impetigo and boils.
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Oral antibiotic therapy (CFPN-PI (CEFCAPENE), 300 mg/day) were started, resulting in gradual improvement of the skin lesion to a PPPASI score of 1 and a VAS score of 2.2 after 2 months
Route of Administration: Oral
A spontaneous rifampin-resistant H. influenzae Rd clone, designated RdRIF (19), and two BLNAR isolates (MSC06647 and MSC06663) were used in this study. Cefcapene activity was determined by the broth dilution method. Cefcapene shows potent antimicrobial activity with MIC 0.008mg/ml (for RdRIF), 0.25mg/ml (for MSC06647) and 2 mg/ml (for MSC06663).
Name Type Language
CEFCAPENE PIVOXIL HYDROCHLORIDE
MI   WHO-DD  
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((AMINOCARBONYL)OXY)METHYL)-7-((2-(2-AMINO-4-THIAZOLYL)-1-OXO-2- PENTENYL)AMINO)-8-OXO-, (2,2-DIMETHYL-1-OXOPROPOXY)METHYL ESTER,(6R- (6-.ALPHA.,7-.BETA.(Z)))-, MONOHYDROCHLORIDE
Common Name English
Cefcapene pivoxil hydrochloride [WHO-DD]
Common Name English
CEFCAPENE PIVOXIL HYDROCHLORIDE ANHYDROUS [MI]
Common Name English
Code System Code Type Description
CAS
147816-23-7
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
PUBCHEM
6918126
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
SMS_ID
100000084964
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID7048582
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
FDA UNII
5J77167P9E
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
MERCK INDEX
m3190
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
EVMPD
SUB01111MIG
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY
MESH
C425944
Created by admin on Fri Dec 15 19:16:16 GMT 2023 , Edited by admin on Fri Dec 15 19:16:16 GMT 2023
PRIMARY